{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:33:49Z","timestamp":1794011629817,"version":"4.8.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2018R1A5A2020732"],"award-info":[{"award-number":["2018R1A5A2020732"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Basic Science and Engineering Research Program","award":["2022R1A2C1009522"],"award-info":[{"award-number":["2022R1A2C1009522"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with fibro-calcific aortic valve disease (FCAVD) have lipid depositions in their aortic valve that engender a proinflammatory impetus toward fibrosis and calcification and ultimately valve leaflet stenosis. Although the lipoprotein(a)-autotaxin (ATX)-lysophosphatidic acid axis has been suggested as a potential therapeutic target to prevent the development of FCAVD, supportive evidence using ATX inhibitors is lacking. We here evaluated the therapeutic potency of an ATX inhibitor to attenuate valvular calcification in the FCAVD animal models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      ATX level and activity in healthy participants and patients with FCAVD were analyzed using a bioinformatics approach using the Gene Expression Omnibus datasets, enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, and western blotting. To evaluate the efficacy of ATX inhibitor, interleukin-1 receptor antagonist-deficient (\n                      <jats:italic>Il1rn<\/jats:italic>\n                      <jats:sup>-\/-)<\/jats:sup>\n                      mice and cholesterol-enriched diet-induced rabbits were used as the FCAVD models, and primary human valvular interstitial cells (VICs) from patients with calcification were employed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The global gene expression profiles of the aortic valve tissue of patients with severe FCAVD demonstrated that ATX gene expression was significantly upregulated and correlated with lipid retention (\n                      <jats:italic>r<\/jats:italic>\n                      = 0.96) or fibro-calcific remodeling-related genes (\n                      <jats:italic>r<\/jats:italic>\n                      = 0.77) in comparison to age-matched non-FCAVD controls. Orally available ATX inhibitor, BBT-877, markedly ameliorated the osteogenic differentiation and further mineralization of primary human VICs in vitro. Additionally, ATX inhibition significantly attenuated fibrosis-related factors\u2019 production, with a detectable reduction of osteogenesis-related factors, in human VICs. Mechanistically, ATX inhibitor prohibited fibrotic changes in human VICs via both canonical and non-canonical TGF-\u03b2 signaling, and subsequent induction of CTGF, a key factor in tissue fibrosis. In the in vivo FCAVD model system, ATX inhibitor exposure markedly reduced calcific lesion formation in interleukin-1 receptor antagonist-deficient mice (\n                      <jats:italic>Il1rn<\/jats:italic>\n                      <jats:sup>-\/-<\/jats:sup>\n                      ,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0210). This inhibition ameliorated the rate of change in the aortic valve area (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0287) and mean pressure gradient (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0249) in the FCAVD rabbit model. Moreover, transaortic maximal velocity (\n                      <jats:italic>V<\/jats:italic>\n                      max) was diminished with ATX inhibitor administration (mean\n                      <jats:italic>V<\/jats:italic>\n                      max = 1.082) compared to vehicle control (mean\n                      <jats:italic>V<\/jats:italic>\n                      max = 1.508,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0221). Importantly, ATX inhibitor administration suppressed the effects of a high-cholesterol diet and vitamin D2-driven fibrosis, in association with a reduction in macrophage infiltration and calcific deposition, in the aortic valves of this rabbit model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ATX inhibition attenuates the development of FCAVD while protecting against fibrosis and calcification in VICs, suggesting the potential of using ATX inhibitors to treat FCAVD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-024-03342-x","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T10:02:32Z","timestamp":1710410552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Autotaxin inhibition attenuates the aortic valve calcification by suppressing inflammation-driven fibro-calcific remodeling of valvular interstitial cells"],"prefix":"10.1186","volume":"22","author":[{"given":"Dohee","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongkun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Hyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jin","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoolim","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ju","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Kwan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"issue":"20","key":"3342_CR1","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1161\/CIRCULATIONAHA.117.027776","volume":"135","author":"E Aikawa","year":"2017","unstructured":"Aikawa E, Libby P. A rock and a hard place: chiseling away at the multiple mechanisms of aortic stenosis. Circulation. 2017;135(20):1951\u20135.","journal-title":"Circulation"},{"issue":"23","key":"3342_CR2","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.jacc.2021.09.1367","volume":"78","author":"BR Lindman","year":"2021","unstructured":"Lindman BR, Sukul D, Dweck MR, Madhavan MV, Arsenault BJ, Coylewright M, et al. Evaluating medical therapy for calcific aortic stenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78(23):2354\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3342_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcmg.2017.10.012","volume":"11","author":"H Mori","year":"2018","unstructured":"Mori H, Torii S, Kutyna M, Sakamoto A, Finn AV, Virmani R. Coronary artery calcification and its progression: what does it really mean? JACC Cardiovasc Imag. 2018;11(1):127\u201342.","journal-title":"JACC Cardiovasc Imag"},{"issue":"11","key":"3342_CR4","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.110.234138","volume":"108","author":"JD Miller","year":"2011","unstructured":"Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res. 2011;108(11):1392\u2013412.","journal-title":"Circ Res"},{"issue":"4","key":"3342_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/CIRCRESAHA.116.309306","volume":"120","author":"L Simard","year":"2017","unstructured":"Simard L, C\u00f4t\u00e9 N, Dagenais F, Mathieu P, Couture C, Trahan S, et al. Sex-related discordance between aortic valve calcification and hemodynamic severity of aortic stenosis: is valvular fibrosis the explanation? Circ Res. 2017;120(4):681\u201391.","journal-title":"Circ Res"},{"key":"3342_CR6","first-page":"918267","volume":"2012","author":"GK Kolluru","year":"2012","unstructured":"Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2012;2012:918267.","journal-title":"Int J Vasc Med"},{"issue":"11","key":"3342_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/hr.2012.138","volume":"35","author":"Y Higashi","year":"2012","unstructured":"Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012;35(11):1039\u201347.","journal-title":"Hypertens Res"},{"key":"3342_CR8","doi-asserted-by":"publisher","unstructured":"Afanasieva OI, Tyurina AV, Klesareva EA, Arefieva TI, Ezhov MV, Pokrovsky SN. Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease. J Pers Med. 2022;12(2):269. https:\/\/doi.org\/10.3390\/jpm12020269.\u00a0Published 2022 Feb 12.","DOI":"10.3390\/jpm12020269"},{"key":"3342_CR9","doi-asserted-by":"publisher","unstructured":"Gliozzi M, Scicchitano M, Bosco F, et al. Modulation of Nitric Oxide Synthases by Oxidized LDLs: Role in Vascular Inflammation and Atherosclerosis Development. Int J Mol Sci. 2019;20(13):3294. https:\/\/doi.org\/10.3390\/ijms20133294.\u00a0 Published 2019 Jul 4.","DOI":"10.3390\/ijms20133294"},{"key":"3342_CR10","doi-asserted-by":"publisher","first-page":"114775","DOI":"10.1016\/j.biopha.2023.114775","volume":"163","author":"L Shu","year":"2023","unstructured":"Shu L, Yuan Z, Li F, Cai Z. Oxidative stress and valvular endothelial cells in aortic valve calcification. Biomed Pharmacother. 2023;163:114775.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3342_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1124\/jpet.110.177915","volume":"337","author":"Z Yu","year":"2011","unstructured":"Yu Z, Seya K, Daitoku K, Motomura S, Fukuda I, Furukawa K. Tumor necrosis factor-\u03b1 accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway. J Pharmacol Exp Ther. 2011;337(1):16\u201323.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"3342_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","volume":"132","author":"R Bouchareb","year":"2015","unstructured":"Bouchareb R, Mahmut A, Nsaibia MJ, Boulanger MC, Dahou A, L\u00e9pine JL, et al. Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation. 2015;132(8):677\u201390.","journal-title":"Circulation."},{"issue":"2","key":"3342_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0021-9150(03)00284-3","volume":"170","author":"JJ Kaden","year":"2003","unstructured":"Kaden JJ, Dempfle CE, Grobholz R, Tran HT, Kili\u00e7 R, Sariko\u00e7 A, et al. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis. 2003;170(2):205\u201311.","journal-title":"Atherosclerosis"},{"issue":"6","key":"3342_CR14","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1194\/jlr.R046391","volume":"55","author":"A Perrakis","year":"2014","unstructured":"Perrakis A, Moolenaar WH. Autotaxin: structure-function and signaling. J Lipid Res. 2014;55(6):1010\u20138.","journal-title":"J Lipid Res"},{"issue":"8","key":"3342_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","volume":"6","author":"TM Maher","year":"2018","unstructured":"Maher TM, van der Aar EM, Van de Steen O, Allamassey L, Desrivot J, Dupont S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018;6(8):627\u201335.","journal-title":"Lancet Respir Med"},{"issue":"20","key":"3342_CR16","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1161\/CIRCULATIONAHA.116.024270","volume":"135","author":"B Choi","year":"2017","unstructured":"Choi B, Lee S, Kim SM, Lee EJ, Lee SR, Kim DH, et al. Dipeptidyl peptidase-4 induces aortic valve calcification by inhibiting insulin-like growth factor-1 signaling in valvular interstitial cells. Circulation. 2017;135(20):1935\u201350.","journal-title":"Circulation"},{"issue":"5","key":"3342_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13543776.2021.1867106","volume":"31","author":"Z Tan","year":"2021","unstructured":"Tan Z, Lei H, Guo M, Chen Y, Zhai X. An updated patent review of autotaxin inhibitors (2017-present). Exp Opin Ther Patents. 2021;31(5):421\u201334.","journal-title":"Exp Opin Ther Patents"},{"issue":"2","key":"3342_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1084\/jem.191.2.313","volume":"191","author":"R Horai","year":"2000","unstructured":"Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000;191(2):313\u201320.","journal-title":"J Exp Med"},{"key":"3342_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.gdata.2015.12.015","volume":"7","author":"J Rys\u00e4","year":"2016","unstructured":"Rys\u00e4 J. Gene expression profiling of human calcific aortic valve disease. Genomics Data. 2016;7:107\u20138.","journal-title":"Genomics Data"},{"issue":"10","key":"3342_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1152\/physiolgenomics.00041.2016","volume":"48","author":"S Guauque-Olarte","year":"2016","unstructured":"Guauque-Olarte S, Droit A, Tremblay-Marchand J, Gaudreault N, Kalavrouziotis D, Dagenais F, et al. RNA expression profile of calcified bicuspid, tricuspid, and normal human aortic valves by RNA sequencing. Physiol Genomics. 2016;48(10):749\u201361.","journal-title":"Physiol Genomics"},{"issue":"1","key":"3342_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12890-021-01670-9","volume":"21","author":"Q Li","year":"2021","unstructured":"Li Q, Wong W, Birnberg A, Chakrabarti A, Yang X, Choy DF, et al. Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease. BMC Pulmon Med. 2021;21(1):301.","journal-title":"BMC Pulmon Med"},{"issue":"4","key":"3342_CR22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1161\/ATVBAHA.119.313067","volume":"40","author":"PR Goody","year":"2020","unstructured":"Goody PR, Hosen MR, Christmann D, Niepmann ST, Zietzer A, Adam M, et al. Aortic valve stenosis: from basic mechanisms to novel therapeutic targets. Arterioscler Thromb Vasc Biol. 2020;40(4):885\u2013900.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"3342_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4110\/in.2016.16.1.26","volume":"16","author":"SH Lee","year":"2016","unstructured":"Lee SH, Choi JH. Involvement of immune cell network in aortic valve stenosis: communication between valvular interstitial cells and immune cells. Immune Netw. 2016;16(1):26\u201332.","journal-title":"Immune Netw"},{"key":"3342_CR24","doi-asserted-by":"publisher","unstructured":"Rutkovskiy A, Malashicheva A, Sullivan G, et al. Valve Interstitial Cells: The Key to Understanding the Pathophysiology of Heart Valve Calcification. J Am Heart Assoc. 2017;6(9):e006339. https:\/\/doi.org\/10.1161\/JAHA.117.006339.\u00a0 Published 2017 Sep 14.","DOI":"10.1161\/JAHA.117.006339"},{"issue":"11","key":"3342_CR25","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1161\/01.ATV.16.11.1365","volume":"16","author":"X Wang","year":"1996","unstructured":"Wang X, Louden C, Ohlstein EH, Stadel JM, Gu JL, Yue TL. Osteopontin expression in platelet-derived growth factor-stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty. Arterioscler Thromb Vasc Biol. 1996;16(11):1365\u201372.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3342_CR26","doi-asserted-by":"publisher","first-page":"660797","DOI":"10.3389\/fcvm.2021.660797","volume":"8","author":"P B\u00fcttner","year":"2021","unstructured":"B\u00fcttner P, Feistner L, Lurz P, Thiele H, Hutcheson JD, Schlotter F. Dissecting calcific aortic valve disease-the role, etiology, and drivers of valvular fibrosis. Front Cardiovasc Med. 2021;8:660797.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"3342_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7150\/ijbs.8.195","volume":"8","author":"E Pardali","year":"2012","unstructured":"Pardali E, Ten Dijke P. TGF\u03b2 signaling and cardiovascular diseases. Int J Biol Sci. 2012;8(2):195\u2013213.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"3342_CR28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1161\/ATVBAHA.109.201749","volume":"30","author":"K Isoda","year":"2010","unstructured":"Isoda K, Matsuki T, Kondo H, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB\/c mice. Arterioscler Thromb Vasc Biol. 2010;30(4):708\u201315.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3342_CR29","first-page":"364310","volume":"2011","author":"KL Sider","year":"2011","unstructured":"Sider KL, Blaser MC, Simmons CA. Animal models of calcific aortic valve disease. Int J Inflamm. 2011;2011:364310.","journal-title":"Int J Inflamm"},{"key":"3342_CR30","doi-asserted-by":"publisher","unstructured":"Choi B, Kim EY, Kim JE, et al. Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification. Cells. 2021;10(1):57. https:\/\/doi.org\/10.3390\/cells10010057.\u00a0Published 2021 Jan 1.","DOI":"10.3390\/cells10010057"},{"issue":"5","key":"3342_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/joim.12519","volume":"280","author":"MJ Nsaibia","year":"2016","unstructured":"Nsaibia MJ, Mahmut A, Boulanger MC, Arsenault BJ, Bouchareb R, Simard S, et al. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. J Intern Med. 2016;280(5):509\u201317.","journal-title":"J Intern Med"},{"key":"3342_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fphar.2017.00461","volume":"8","author":"KL Walton","year":"2017","unstructured":"Walton KL, Johnson KE, Harrison CA. Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis. Front Pharmacol. 2017;8:461.","journal-title":"Front Pharmacol"},{"issue":"17","key":"3342_CR33","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/jama.2014.13959","volume":"312","author":"JG Smith","year":"2014","unstructured":"Smith JG, Luk K, Schulz CA, Engert JC, Do R, Hindy G, et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 2014;312(17):1764\u201371.","journal-title":"JAMA"},{"issue":"7","key":"3342_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacbts.2020.05.004","volume":"5","author":"N Perrot","year":"2020","unstructured":"Perrot N, Valerio V, Moschetta D, Boekholdt SM, Dina C, Chen HY, et al. Genetic and in vitro inhibition of PCSK9 and calcific aortic valve stenosis. JACC Basic Transl Sci. 2020;5(7):649\u201361.","journal-title":"JACC Basic Transl Sci"},{"issue":"6","key":"3342_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","volume":"368","author":"G Thanassoulis","year":"2013","unstructured":"Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503\u201312.","journal-title":"N Engl J Med"},{"issue":"17","key":"3342_CR36","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","volume":"73","author":"KH Zheng","year":"2019","unstructured":"Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WSA, Doris MK, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73(17):2150\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3342_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","volume":"5","author":"BA Bergmark","year":"2020","unstructured":"Bergmark BA, O\u2019Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Ce\u0161ka R, et al. An Exploratory analysis of proprotein convertase subtilisin\/kexin type 9 inhibition and aortic stenosis in the FOURIER trial. JAMA Cardiol. 2020;5(6):709\u201313.","journal-title":"JAMA Cardiol"},{"issue":"12","key":"3342_CR38","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O'Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483\u201392.","journal-title":"Circulation"},{"issue":"18","key":"3342_CR39","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"3342_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3342_CR41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355.","journal-title":"N Engl J Med"},{"issue":"16","key":"3342_CR42","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"11","key":"3342_CR43","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/cvr\/cvx089","volume":"113","author":"MJ Nsaibia","year":"2017","unstructured":"Nsaibia MJ, Boulanger MC, Bouchareb R, Mkannez G, Le Quang K, Hadji F, et al. OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-\u03baB pathway. Cardiovasc Res. 2017;113(11):1351\u201363.","journal-title":"Cardiovasc Res"},{"issue":"50","key":"3342_CR44","doi-asserted-by":"publisher","first-page":"48737","DOI":"10.1074\/jbc.M206812200","volume":"277","author":"J Aoki","year":"2002","unstructured":"Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277(50):48737\u201344.","journal-title":"J Biol Chem"},{"issue":"17","key":"3342_CR45","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/eurheartj\/ehy696","volume":"40","author":"R Bouchareb","year":"2019","unstructured":"Bouchareb R, Boulanger MC, Tastet L, Mkannez G, Nsaibia MJ, Hadji F, et al. Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis. Eur Heart J. 2019;40(17):1362\u201373.","journal-title":"Eur Heart J"},{"issue":"3","key":"3342_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jacbts.2017.02.004","volume":"2","author":"M Torzewski","year":"2017","unstructured":"Torzewski M, Ravandi A, Yeang C, Edel A, Bhindi R, Kath S, et al. Lipoprotein(a) associated molecules are prominent components in plasma and valve leaflets in calcific aortic valve stenosis. JACC Basic Transl Sci. 2017;2(3):229\u201340.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"3342_CR47","doi-asserted-by":"publisher","first-page":"851","DOI":"10.4049\/jimmunol.1302831","volume":"192","author":"S Knowlden","year":"2014","unstructured":"Knowlden S, Georas SN. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J Immunol (Baltimore, Md: 1950). 2014;192(3):851\u20137.","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"1","key":"3342_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nm1685","volume":"14","author":"AM Tager","year":"2008","unstructured":"Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14(1):45\u201354.","journal-title":"Nat Med"},{"issue":"5","key":"3342_CR49","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1165\/rcmb.2012-0004OC","volume":"47","author":"N Oikonomou","year":"2012","unstructured":"Oikonomou N, Mouratis MA, Tzouvelekis A, Kaffe E, Valavanis C, Vilaras G, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;47(5):566\u201374.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"3342_CR50","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nm1060","volume":"10","author":"M Inoue","year":"2004","unstructured":"Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med. 2004;10(7):712\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"3342_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/ATVBAHA.113.302737","volume":"34","author":"SS Smyth","year":"2014","unstructured":"Smyth SS, Mueller P, Yang F, Brandon JA, Morris AJ. Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34(3):479\u201386.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3342_CR52","doi-asserted-by":"crossref","unstructured":"Kremer AE, Martens JJ, Kulik W, Ru\u00ebff F, Kuiper EM, van Buuren HR, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139(3):1008-18, 18.e1.","DOI":"10.1053\/j.gastro.2010.05.009"},{"issue":"3\u20134","key":"3342_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10555-011-9319-7","volume":"30","author":"AJ Houben","year":"2011","unstructured":"Houben AJ, Moolenaar WH. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 2011;30(3\u20134):557\u201365.","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"3342_CR54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ccr.2009.03.027","volume":"15","author":"S Liu","year":"2009","unstructured":"Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009;15(6):539\u201350.","journal-title":"Cancer Cell"},{"issue":"17","key":"3342_CR55","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/jnci\/djs319","volume":"104","author":"JC Marshall","year":"2012","unstructured":"Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, Steinberg SM, et al. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst. 2012;104(17):1306\u201319.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3342_CR56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.bbalip.2012.06.004","volume":"1831","author":"O Peyruchaud","year":"2013","unstructured":"Peyruchaud O, Leblanc R, David M. Pleiotropic activity of lysophosphatidic acid in bone metastasis. Biochimica et biophysica acta. 2013;1831(1):99\u2013104.","journal-title":"Biochimica et biophysica acta"},{"issue":"12","key":"3342_CR57","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00109-020-01997-6","volume":"98","author":"Z Wang","year":"2020","unstructured":"Wang Z, Shi W, Tian D, Qin H, Vallance BA, Yang H, et al. Autotaxin stimulates LPA2 receptor in macrophages and exacerbates dextran sulfate sodium-induced acute colitis. J Mol Med (Berl). 2020;98(12):1781\u201394.","journal-title":"J Mol Med (Berl)"},{"issue":"6","key":"3342_CR58","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1165\/rcmb.2013-0070OC","volume":"49","author":"LS Huang","year":"2013","unstructured":"Huang LS, Fu P, Patel P, Harijith A, Sun T, Zhao Y, et al. Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice. Am J Respir Cell Mol Biol. 2013;49(6):912\u201322.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"3342_CR59","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1084\/jem.20112012","volume":"209","author":"I Nikitopoulou","year":"2012","unstructured":"Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med. 2012;209(5):925\u201333.","journal-title":"J Exp Med"},{"key":"3342_CR60","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fmed.2018.00180","volume":"5","author":"I Ninou","year":"2018","unstructured":"Ninou I, Magkrioti C, Aidinis V. Autotaxin in pathophysiology and pulmonary fibrosis. Front Med. 2018;5:180.","journal-title":"Front Med"},{"issue":"1","key":"3342_CR61","doi-asserted-by":"publisher","first-page":"e000422","DOI":"10.1136\/bmjresp-2019-000422","volume":"6","author":"TM Maher","year":"2019","unstructured":"Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, et al. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respir Res. 2019;6(1):e000422.","journal-title":"BMJ Open Respir Res"},{"issue":"7","key":"3342_CR62","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/j.1476-5381.2010.00828.x","volume":"160","author":"JS Swaney","year":"2010","unstructured":"Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, Prodanovich PC, et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol. 2010;160(7):1699\u2013713.","journal-title":"Br J Pharmacol"},{"key":"3342_CR63","doi-asserted-by":"publisher","unstructured":"Corte TJ, Lancaster L, Swigris JJ, et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1\u00a0(LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease\u00a0(PF-ILD). BMJ Open Respir Res. 2021;8(1):e001026. https:\/\/doi.org\/10.1136\/bmjresp-2021-001026.","DOI":"10.1136\/bmjresp-2021-001026"},{"issue":"19","key":"3342_CR64","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.jacc.2012.02.093","volume":"60","author":"MR Dweck","year":"2012","unstructured":"Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60(19):1854\u201363.","journal-title":"J Am Coll Cardiol"}],"updated-by":[{"DOI":"10.1186\/s12916-024-03403-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000}}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03342-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03342-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03342-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T21:02:21Z","timestamp":1714338141000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03342-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3342"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03342-x","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"25 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12916-024-03403-1","URL":"https:\/\/doi.org\/10.1186\/s12916-024-03403-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research for this study was approved by the Institutional Review Board of Asan Medical Center (Seoul, Republic of Korea), and all patients provided informed consent for the use of their clinical specimens for research (No. 2017-0556 for tissues and No. 2019-0965 for serums). And all animal experiments were approved by the Institutional Committee for the Use and Care of Laboratory animals of Ulsan University (No. 2022-12-183).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial or other interests in relation to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}